Abstract:Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. In this paper, we describe a series of novel cyclic peptides derived from an mRNA display screen which inhibit the protein–protein interaction between PCSK9 and LDLR. Using a structure-based drug design approach, we were able to modify our original screening lead 2 to optimize the potency and metabolic stability and minimize the molecular weight to provide novel bicyclic next-generation PCSK9 inhibitor peptides such as 78. These next-generation peptides serve as a critical foundation for continued exploration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01084?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01084</a>.Representative LC traces for key molecules in the paper, sample IC50 curves for LDLR-FRET and Alexa-FRET assay control peptide, and raw concentration versus time profiles for molecules tested in Mouse IV PK 3D PDB files for each of the new crystal structures have also been uploaded; PDB codes for the crystal structures shown in the paper are as follows: compound 30, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIB">6XIB</a>; compound 40, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIC">6XIC</a>; compound 51, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XID">6XID</a>; compound 78, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIE">6XIE</a>; and compound 84, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XIF">6XIF</a>; and authors will release the atomic coordinates and experimental data upon article publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_001.pdf">PDF</a>)6xib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_002.pdb">PDB</a>)6xic (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_003.pdb">PDB</a>)6xid (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_004.pdb">PDB</a>)6xie (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_005.pdb">PDB</a>)6xif (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01084/suppl_file/jm0c01084_si_006.pdb">PDB</a>)This article has not yet been cited by other publications.

Stereochemical assignment of clerodane-type diterpenes from the fruits of Casearia grewiifolia and their ability to inhibit PCSK9 expression

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Acyclic Triterpenoids from Alpinia katsumadai Seeds with Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Secretion Inhibitory Activity

Novel triterpenoids from <i>Alisma plantago-aquatica</i> with influence on LDL uptake in HepG2 cells by inhibiting PCSK9

Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.

Amide alkaloids and neolignans from Piper hongkongense and their inhibitory activities of PCSK9 expression

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro

Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis

Caseatardies A-K, eleven undescribed clerodane diterpenoids isolated from Casearia tardieuae and their anti-inflammatory activity

Discovery of 2,3'-Diindolylmethanes As a Novel Class of PCSK9 Modulators.

Dolabellane and Clerodane Diterpenoids from the Twigs and Leaves of Casearia kurzii

Novel Jatrophane Diterpenoids from Euphorbia esul a Promotes Lipid Clearance by Transcriptional Regulation of PCSK9

Novel Jatrophane Diterpenoids from Euphorbia Esula Promotes Lipid Clearance by Transcriptional Regulation of PCSK9

Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Bioactive Diterpenoids Isolated from the Twigs and Leaves of Casearia Velutina.

Identification of new PTP1B-inhibiting decipiene diterpenoid esters from Eremophila clarkei by high-resolution PTP1B inhibition profiling, enzyme kinetics analysis, and molecular docking

New clerodane diterpenoids from Casearia sylvestris.

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design